|
Summary Information: Viracta Therapeutics Inc. Common Stock NASDAQ:VIRX |
  admin@troach.net |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
__The following are links to various summary and news pages for __Viracta Therapeutics Inc. Common Stock [ VIRX ]. __Note: Some Links might not have information for the company. |
|